<!DOCTYPE html>
<html lang="tr">
<head>
<link rel="alternate" hreflang="tr" href="https://uzunyasa.com/pages/blog/karaciger-yaglanmasi-masld-endobariatrik-tedavi.html">
<link rel="alternate" hreflang="x-default" href="https://uzunyasa.com/pages/blog/karaciger-yaglanmasi-masld-endobariatrik-tedavi.html">
<meta http-equiv="Content-Language" content="tr">
<link rel="icon" type="image/png" sizes="32x32" href="/favicon.png"><link rel="icon" type="image/png" sizes="16x16" href="/favicon-16.png">
<script>if(location.protocol!=="https:"&&location.hostname!=="localhost"&&location.hostname!=="127.0.0.1")location.replace("https://"+location.host+location.pathname+location.search+location.hash);</script>
<!-- Google tag (gtag.js) -->
<script async src="https://www.googletagmanager.com/gtag/js?id=G-QBM7E0EHFP"></script>
<script>
 window.dataLayer = window.dataLayer || [];
 function gtag(){dataLayer.push(arguments);}
 gtag('js', new Date());
 gtag('config', 'G-QBM7E0EHFP');
</script>
 <meta charset="UTF-8">
 <meta name="viewport" content="width=device-width, initial-scale=1.0">
 <title>KaraciÄŸer YaÄŸlanmasÄ±nda (MASLD) Endobariatrik Tedavi: Cerrahisiz Ã‡Ã¶zÃ¼mler | UzunYaÅŸa Blog</title>
    <meta property="og:image" content="https://uzunyasa.com/images/og-default.png">
 <meta name="description" content="MASLD (karaciÄŸer yaÄŸlanmasÄ±) tedavisinde endoskopik sleeve gastroplasti (ESG), intragastrik balon ve GLP-1 ilaÃ§larÄ±nÄ±n rolÃ¼. Cerrahisiz seÃ§eneklerin kanÄ±ta dayalÄ± deÄŸerlendirmesi, sÄ±nÄ±rlÄ±lÄ±klarÄ± ve kombinasyon potansiyeli.">
 <link rel="preconnect" href="https://fonts.googleapis.com">
 <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
 <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700;800&display=swap" rel="stylesheet">
 <link rel="preload" href="../../styles/main.css" as="style">
 <link rel="stylesheet" href="../../styles/main.css">
 <link rel="preload" href="../../styles/animations.css" as="style">
 <link rel="stylesheet" href="../../styles/animations.css">
 <style>
 article { max-width: 700px; margin: 0 auto; padding: 7rem 2rem 4rem; }
 .post-category { display: inline-block; background: #EC4899; color: white; padding: 0.4rem 1rem; border-radius: 20px; font-size: 0.8rem; font-weight: 600; margin-bottom: 1rem; }
 h1 { font-size: 2.5rem; font-weight: 800; line-height: 1.2; margin-bottom: 1rem; color: var(--text); }
 .post-meta { color: var(--text-gray); margin-bottom: 2rem; font-size: 0.9rem; }
 .featured-image { width: 100%; height: 350px; background: linear-gradient(135deg, #1a3c34 0%, #0d5c3f 50%, #2d8659 100%); border-radius: 16px; margin-bottom: 2rem; display: flex; align-items: center; justify-content: center; font-size: 5rem; }
 .content p { margin-bottom: 1.5rem; font-size: 1.1rem; }
 .content h2 { font-size: 1.5rem; font-weight: 700; margin: 2.5rem 0 1rem; color: var(--primary); }
 .content h3 { font-size: 1.3rem; font-weight: 600; margin: 2rem 0 1rem; color: var(--text); }
 .content ul, .content ol { margin: 1.5rem 0; padding-left: 1.5rem; }
 .content li { margin-bottom: 0.75rem; font-size: 1.05rem; }
 .highlight-box { background: #f0fdf4; border-left: 4px solid #10b981; padding: 1.5rem; border-radius: 0 12px 12px 0; margin: 2rem 0; }
 .stat-box { background: var(--primary); color: white; padding: 2rem; border-radius: 16px; text-align: center; margin: 2rem 0; }
 .stat-box .number { font-size: 3rem; font-weight: 800; }
 .stat-box .label { opacity: 0.9; }
 .cta-box { background: linear-gradient(135deg, var(--primary), #2a7d83); color: white; padding: 2rem; border-radius: 16px; text-align: center; margin: 3rem 0; }
 .cta-btn { display: inline-block; background: white; color: var(--primary); padding: 0.75rem 1.5rem; border-radius: 8px; text-decoration: none; font-weight: 600; }

 .warning-box { background: #fef3c7; border: 2px solid #f59e0b; border-radius: 12px; padding: 1.5rem; margin: 2rem 0; }
 .warning-box h4 { color: #92400e; margin-bottom: 0.5rem; }

 .evidence-box { background: #f8fafc; border-radius: 16px; padding: 2rem; margin: 2rem 0; border: 1px solid #e2e8f0; }
 .evidence-positive { background: #f0fdf4; border-left: 5px solid #10b981; padding: 1.25rem; border-radius: 0 12px 12px 0; margin: 1rem 0; }
 .evidence-negative { background: #fef2f2; border-left: 5px solid #ef4444; padding: 1.25rem; border-radius: 0 12px 12px 0; margin: 1rem 0; }
 .evidence-neutral { background: #eff6ff; border-left: 5px solid #3b82f6; padding: 1.25rem; border-radius: 0 12px 12px 0; margin: 1rem 0; }

 .study-card { background: white; border: 1px solid #e5e7eb; border-radius: 12px; padding: 1.5rem; margin: 1.5rem 0; box-shadow: 0 1px 3px rgba(0,0,0,0.1); }
 .study-card h4 { margin: 0 0 0.75rem; font-size: 1.1rem; color: var(--primary); }
 .study-card .study-detail { font-size: 0.95rem; margin-bottom: 0.5rem; }
 .study-card .study-detail strong { color: #374151; }

 .key-stat-box { background: linear-gradient(135deg, #f0fdfa, #ecfdf5); border-left: 5px solid #0D7377; border-radius: 0 16px 16px 0; padding: 1.5rem 2rem; margin: 2rem 0; display: flex; align-items: center; gap: 1.25rem; }
 .key-stat-box .ks-number { font-size: 2.5rem; font-weight: 800; color: #0D7377; line-height: 1; white-space: nowrap; }
 .key-stat-box .ks-context { font-size: 0.95rem; color: #195157; line-height: 1.5; }
 .key-stat-box.accent { border-left-color: #E8963E; background: linear-gradient(135deg, #fffbeb, #fef3c7); }
 .key-stat-box.accent .ks-number { color: #E8963E; }
 .key-stat-box.red { border-left-color: #ef4444; background: linear-gradient(135deg, #fef2f2, #fee2e2); }
 .key-stat-box.red .ks-number { color: #ef4444; }

 .turkey-box { background: linear-gradient(135deg, #fdf2f8, #fce7f3); border-left: 5px solid #ec4899; border-radius: 0 16px 16px 0; padding: 1.5rem 2rem; margin: 2rem 0; }
 .turkey-box h4 { color: #be185d; margin-bottom: 0.75rem; }

 .comparison-table { width: 100%; border-collapse: collapse; margin: 2rem 0; font-size: 0.95rem; }
 .comparison-table th { background: #0D7377; color: white; padding: 0.75rem; text-align: left; }
 .comparison-table td { padding: 0.75rem; border-bottom: 1px solid #e5e7eb; }
 .comparison-table tr:nth-child(even) { background: #f8fafc; }

 @media (max-width: 640px) { h1 { font-size: 1.8rem; } article { padding: 6rem 1rem 3rem; } .featured-image { height: 220px; font-size: 3.5rem; } .key-stat-box .ks-number { font-size: 1.8rem; } .key-stat-box { flex-direction: column; text-align: center; } .comparison-table { font-size: 0.8rem; } .comparison-table th, .comparison-table td { padding: 0.5rem; } }
 </style>

    <meta property="og:title" content="KaraciÄŸer YaÄŸlanmasÄ±nda (MASLD) Endobariatrik Tedavi: Cerrahisiz Ã‡Ã¶zÃ¼mler">
    <meta property="og:description" content="MASLD tedavisinde endoskopik sleeve gastroplasti, intragastrik balon ve GLP-1 ilaÃ§larÄ±nÄ±n kanÄ±ta dayalÄ± deÄŸerlendirmesi.">
    <meta property="og:type" content="article">
    <meta property="og:url" content="https://uzunyasa.com/pages/blog/karaciger-yaglanmasi-masld-endobariatrik-tedavi.html">
    <meta property="og:image" content="https://uzunyasa.com/images/og-default.png">
    <meta property="og:site_name" content="UzunYaÅŸa">
    <meta property="og:locale" content="tr_TR">
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:title" content="KaraciÄŸer YaÄŸlanmasÄ±nda (MASLD) Endobariatrik Tedavi: Cerrahisiz Ã‡Ã¶zÃ¼mler">
    <meta name="twitter:description" content="MASLD tedavisinde endoskopik sleeve gastroplasti, intragastrik balon ve GLP-1 ilaÃ§larÄ±nÄ±n kanÄ±ta dayalÄ± deÄŸerlendirmesi.">
    <link rel="canonical" href="https://uzunyasa.com/pages/blog/karaciger-yaglanmasi-masld-endobariatrik-tedavi.html">
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "Article",
  "headline": "KaraciÄŸer YaÄŸlanmasÄ±nda (MASLD) Endobariatrik Tedavi: Cerrahisiz Ã‡Ã¶zÃ¼mler",
  "description": "MASLD (karaciÄŸer yaÄŸlanmasÄ±) tedavisinde endoskopik sleeve gastroplasti (ESG), intragastrik balon ve GLP-1 ilaÃ§larÄ±nÄ±n rolÃ¼. Cerrahisiz seÃ§eneklerin kanÄ±ta dayalÄ± deÄŸerlendirmesi, sÄ±nÄ±rlÄ±lÄ±klarÄ± ve kombinasyon potansiyeli.",
  "author": {
    "@type": "Person",
    "name": "Prof. Dr. Cem ÅimÅŸek",
    "url": "https://uzunyasa.com",
    "jobTitle": "Gastroenterolog & Endoskopist"
  },
  "publisher": {
    "@type": "Organization",
    "name": "UzunYaÅŸa",
    "logo": {
      "@type": "ImageObject",
      "url": "https://uzunyasa.com/images/logo-icon-new.png"
    }
  },
  "datePublished": "2026-02-28",
  "dateModified": "2026-02-28",
  "mainEntityOfPage": "https://uzunyasa.com/pages/blog/karaciger-yaglanmasi-masld-endobariatrik-tedavi.html",
  "image": "https://uzunyasa.com/images/og-default.png",
  "keywords": ["MASLD", "NAFLD", "karaciÄŸer yaÄŸlanmasÄ±", "endobariatrik tedavi", "ESG", "endoskopik sleeve gastroplasti", "intragastrik balon", "GLP-1", "semaglutid", "resmetirom", "MASH", "NASH", "cerrahisiz kilo verme", "bariatrik endoskopi"],
  "articleSection": "Tedavi",
  "wordCount": "2800",
  "medicalAudience": ["Patients", "Healthcare Professionals"]
}
</script>
</head>
<body>
 <header class="header">
 <div class="header-inner">
 <a href="../../index.html"><img src="../../images/logo.svg" alt="UzunYaÅŸa" class="logo-img"></a>
 <a href="../blog.html" class="back-link">â† Blog</a>
 </div>
 </header>

 <article>
 <span class="post-category">ğŸ’Š Tedavi</span>
 <h1>KaraciÄŸer YaÄŸlanmasÄ±nda (MASLD) Endobariatrik Tedavi: Cerrahisiz Ã‡Ã¶zÃ¼mler</h1>
 <div class="post-meta">28 Åubat 2026 â€¢ â± 15 dk okuma</div>

 <div class="featured-image">ğŸ«</div>

 <div class="content">

<div class="warning-box">
<h4>âš ï¸ Ã–nemli Not</h4>
<p>Endoskopik bariatrik prosedÃ¼rler (ESG, intragastrik balon) henÃ¼z <strong>MASLD/MASH iÃ§in spesifik endikasyon almamÄ±ÅŸtÄ±r</strong>. Bu yazÄ±da sunulan kanÄ±tlar obezite tedavisi baÄŸlamÄ±nda elde edilen sonuÃ§larÄ± yansÄ±tmaktadÄ±r. KaraciÄŸer yaÄŸlanmasÄ± Ã¼zerine etkileri dolaylÄ± olarak â€” kilo kaybÄ± aracÄ±lÄ±ÄŸÄ±yla â€” gerÃ§ekleÅŸmektedir. Tedavi kararlarÄ± bireysel olarak, uzman hekim eÅŸliÄŸinde verilmelidir.</p>
</div>

<p>KaraciÄŸer yaÄŸlanmasÄ±, dÃ¼nya genelinde en yaygÄ±n kronik karaciÄŸer hastalÄ±ÄŸÄ± haline gelmiÅŸtir. 2023 yÄ±lÄ±nda uluslararasÄ± konsensusla adÄ± deÄŸiÅŸen bu hastalÄ±k â€” artÄ±k <strong>MASLD (Metabolik Disfonksiyon ile Ä°liÅŸkili Steatotik KaraciÄŸer HastalÄ±ÄŸÄ±)</strong> olarak biliniyor â€” yalnÄ±zca karaciÄŸeri deÄŸil, tÃ¼m metabolik sistemi etkileyen ciddi bir saÄŸlÄ±k sorunudur.</p>

<p>Peki cerrahiye alternatif, endoskopik yÃ¶ntemlerle saÄŸlanan kilo kaybÄ± bu hastalÄ±ÄŸÄ±n seyrini deÄŸiÅŸtirebilir mi? Bu yazÄ±da, endoskopik sleeve gastroplasti (ESG), intragastrik balon, farmakolojik tedaviler ve bunlarÄ±n kombinasyon potansiyelini â€” olumlu <em>ve</em> olumsuz kanÄ±tlarÄ±yla birlikte â€” inceliyoruz.</p>

<h2>ğŸ“‹ Ã–nce Terminoloji: NAFLD'den MASLD'ye</h2>

<p>2023 yÄ±lÄ±nda, Ã§ok toplumlu bir Delphi konsensus paneli ile karaciÄŸer yaÄŸlanmasÄ± hastalÄ±klarÄ±nÄ±n isimlendirmesi kÃ¶klÃ¼ biÃ§imde deÄŸiÅŸtirildi (<a href="https://pubmed.ncbi.nlm.nih.gov/37363821/" target="_blank" rel="noopener">Rinella et al., Hepatology 2023; PMID: 37363821</a>).</p>

<div class="highlight-box">
<strong>Eski â†’ Yeni terminoloji:</strong>
<ul style="margin-top:0.5rem;">
<li><strong>NAFLD</strong> (Non-Alcoholic Fatty Liver Disease) â†’ <strong>MASLD</strong> (Metabolic dysfunction-Associated Steatotic Liver Disease)</li>
<li><strong>NASH</strong> (Non-Alcoholic Steatohepatitis) â†’ <strong>MASH</strong> (Metabolic dysfunction-Associated Steatohepatitis)</li>
</ul>
<p style="margin-bottom:0; margin-top:1rem; font-size:0.95rem;">Neden deÄŸiÅŸti? Eski isimlendirme "alkolik olmayan" tanÄ±mÄ±na dayanÄ±yordu â€” bu hem stigmatize edici bulundu hem de hastalÄ±ÄŸÄ±n metabolik doÄŸasÄ±nÄ± yansÄ±tmÄ±yordu. Yeni isim, en az bir kardiyometabolik risk faktÃ¶rÃ¼nÃ¼n (obezite, diyabet, hipertansiyon, dislipidemi, bel Ã§evresi artÄ±ÅŸÄ±) varlÄ±ÄŸÄ±nÄ± ÅŸart koÅŸar. Ã–nceki NAFLD tanÄ±lÄ± hastalarÄ±n <strong>&gt;%96'sÄ±</strong> MASLD kriterlerini de karÅŸÄ±lamaktadÄ±r.</p>
</div>

<p><strong>Bu yazÄ±da</strong> gÃ¼ncel isimlendirmeyi (MASLD/MASH) kullanÄ±yoruz; ancak atÄ±f yapÄ±lan Ã§alÄ±ÅŸmalarÄ±n Ã§oÄŸu NAFLD/NASH dÃ¶neminde yapÄ±ldÄ±ÄŸÄ±ndan, orijinal terimler de geÃ§ecektir.</p>

<h2>ğŸ“Š MASLD: Ne Kadar YaygÄ±n?</h2>

<div class="key-stat-box">
<div class="ks-number">%32</div>
<div class="ks-context">DÃ¼nya genelinde MASLD prevalansÄ±. Her 3 yetiÅŸkinden biri karaciÄŸer yaÄŸlanmasÄ± ile yaÅŸÄ±yor (meta-analiz, 2022).</div>
</div>

<div class="key-stat-box accent">
<div class="ks-number">%48</div>
<div class="ks-context">TÃ¼rkiye'de NAFLD/MASLD prevalansÄ± â€” dÃ¼nya ortalamasÄ±nÄ±n Ã§ok Ã¼zerinde. 50 yaÅŸ Ã¼stÃ¼ grupta bu oran %65'e ulaÅŸÄ±yor (<a href="https://pubmed.ncbi.nlm.nih.gov/34160360/" target="_blank" rel="noopener" style="color:#92400e;">PMID: 34160360</a>).</div>
</div>

<p>TÃ¼rkiye'deki yÃ¼ksek obezite oranÄ± (~%32, OECD 2024), Tip 2 diyabet prevalansÄ± ve BatÄ±laÅŸan beslenme alÄ±ÅŸkanlÄ±klarÄ± bu tabloyu doÄŸrudan beslemektedir. Tarama Ã§alÄ±ÅŸmalarÄ±nda TÃ¼rk popÃ¼lasyonunda MASLD sÄ±klÄ±ÄŸÄ± %48-60 aralÄ±ÄŸÄ±nda raporlanmÄ±ÅŸtÄ±r.</p>

<h2>ğŸ¯ Tedavinin Temeli: Kilo KaybÄ± Hedefleri</h2>

<p>2024 yÄ±lÄ±nda gÃ¼ncellenen EASL-EASD-EASO ortak kÄ±lavuzu (<a href="https://pubmed.ncbi.nlm.nih.gov/38851997/" target="_blank" rel="noopener">PMID: 38851997</a>), MASLD tedavisinde kilo kaybÄ±nÄ±n doz-yanÄ±t iliÅŸkisini net biÃ§imde ortaya koyar:</p>

<div class="evidence-box">
<h3 style="margin-top:0;">Kilo KaybÄ± ve KaraciÄŸer Ãœzerine Etki (EASL 2024)</h3>
<ul>
<li><strong>â‰¥%5 kilo kaybÄ±:</strong> KaraciÄŸer yaÄŸlanmasÄ±nda (steatoz) azalma</li>
<li><strong>%7-10 kilo kaybÄ±:</strong> KaraciÄŸer iltihabÄ±nda (inflamasyon/MASH) iyileÅŸme</li>
<li><strong>â‰¥%10 kilo kaybÄ±:</strong> Fibroziste (skar dokusu) gerileme potansiyeli</li>
</ul>
<p style="margin-bottom:0;"><strong>Sorun:</strong> YaÅŸam tarzÄ± mÃ¼dahalesi ile hastalarÄ±n yalnÄ±zca kÃ¼Ã§Ã¼k bir kÄ±smÄ± â‰¥%10 kilo kaybÄ±na ulaÅŸabilmektedir. Bu da farmakolojik ve prosedÃ¼rel yaklaÅŸÄ±mlarÄ±n Ã¶nemini artÄ±rmaktadÄ±r.</p>
</div>

<p>Ä°ÅŸte endoskopik bariatrik prosedÃ¼rler tam bu boÅŸluÄŸa hitap eder: yaÅŸam tarzÄ± mÃ¼dahalesinden fazla, bariatrik cerrahiden daha az invaziv bir ara basamak sunarak hastalarÄ±n klinik olarak anlamlÄ± kilo kaybÄ±na ulaÅŸmasÄ±na yardÄ±mcÄ± olabilirler.</p>

<h2>ğŸ”¬ Endoskopik Sleeve Gastroplasti (ESG) ve KaraciÄŸer YaÄŸlanmasÄ±</h2>

<p>Endoskopik sleeve gastroplasti (ESG), aÄŸÄ±z yoluyla yerleÅŸtirilen bir dikiÅŸ cihazÄ±yla mide hacminin endoluminal olarak kÃ¼Ã§Ã¼ltÃ¼ldÃ¼ÄŸÃ¼, <strong>kesi gerektirmeyen</strong> bir prosedÃ¼rdÃ¼r. Genel anestezi altÄ±nda yaklaÅŸÄ±k 60-90 dakika sÃ¼rer ve hasta genellikle aynÄ± veya ertesi gÃ¼n taburcu olur.</p>

<h3>ESG ve MASLD: Meta-Analiz Verileri</h3>

<div class="study-card">
<h4>ğŸŸ¡ Nunes et al. â€” ESG ve NAFLD Meta-Analizi (2023)</h4>
<div class="study-detail"><strong>Kaynak:</strong> Obes Surg 2023;33(9):2917-2926 (<a href="https://pubmed.ncbi.nlm.nih.gov/37537506/" target="_blank" rel="noopener">PMID: 37537506</a>)</div>
<div class="study-detail"><strong>PopÃ¼lasyon:</strong> 4 gÃ¶zlemsel Ã§alÄ±ÅŸma, toplam 175 NAFLD hastasÄ±</div>
<div class="study-detail"><strong>MÃ¼dahale:</strong> ESG, 12 ay takip</div>
<div class="study-detail"><strong>SonuÃ§lar:</strong> Hepatik steatoz indeksinde (HSI) anlamlÄ± dÃ¼ÅŸÃ¼ÅŸ: âˆ’4.85 (95% GA: âˆ’6.02, âˆ’3.67); NAFLD fibrozis skorunda âˆ’0.5; ALT âˆ’6.32 U/L; toplam kilo kaybÄ± (TWL) %17.28; HbA1c âˆ’%0.51</div>
<div class="study-detail"><strong>âš ï¸ SÄ±nÄ±rlÄ±lÄ±k:</strong> TÃ¼m Ã§alÄ±ÅŸmalar gÃ¶zlemsel ve kÃ¼Ã§Ã¼k Ã¶lÃ§ekli; kontrol grubu yok. KaraciÄŸer biyopsisi ile doÄŸrulama yapÄ±lmamÄ±ÅŸ.</div>
</div>

<h3>Ä°lk Sham-KontrollÃ¼ RCT: ESG ve MASH</h3>

<div class="study-card">
<h4>ğŸŸ¡ Llop et al. â€” ESG + YaÅŸam TarzÄ± vs Sham RCT (2025)</h4>
<div class="study-detail"><strong>Kaynak:</strong> Clin Gastroenterol Hepatol 2025;23(9):1556-1566 (<a href="https://pubmed.ncbi.nlm.nih.gov/39694202/" target="_blank" rel="noopener">PMID: 39694202</a>)</div>
<div class="study-detail"><strong>PopÃ¼lasyon:</strong> 40 hasta, biyopsi ile kanÄ±tlanmÄ±ÅŸ MASH (NAS â‰¥3, F0-F3)</div>
<div class="study-detail"><strong>MÃ¼dahale:</strong> ESG + yaÅŸam tarzÄ± mÃ¼dahalesi vs sham endoskopi + yaÅŸam tarzÄ±, 72 hafta</div>
<div class="study-detail"><strong>Primer sonuÃ§lar:</strong>
<ul>
<li>Toplam kilo kaybÄ±: ESG %9.47 vs sham %3.91 (P &lt; 0.05)</li>
<li>KaraciÄŸer sertliÄŸi (FibroScan): ESG âˆ’5.63 KPa vs sham âˆ’0.2 KPa (P &lt; 0.05)</li>
<li>Steatoz skoru: ESG âˆ’0.94 vs sham âˆ’0.26 (P = 0.033)</li>
</ul></div>
<div class="study-detail"><strong>âš ï¸ SÄ±nÄ±rlÄ±lÄ±k:</strong> Ã‡ok kÃ¼Ã§Ã¼k Ã¶rneklem (N=40); Ã§ok merkezli ama kanÄ±t dÃ¼zeyi henÃ¼z kesin sonuÃ§ Ã§Ä±karmak iÃ§in yetersiz. Bununla birlikte, <strong>MASLD/MASH alanÄ±nda ESG ile yapÄ±lmÄ±ÅŸ ilk sham-kontrollÃ¼ RCT</strong> olmasÄ± aÃ§Ä±sÄ±ndan Ã¶nemli bir kilometre taÅŸÄ±.</div>
</div>

<div class="evidence-neutral">
<strong>âš–ï¸ ESG ve MASLD Ä°Ã§in Net Durum:</strong> ESG, non-invaziv testlerle deÄŸerlendirilen steatoz ve fibrozis parametrelerinde iyileÅŸme saÄŸlamaktadÄ±r. Ancak mevcut veriler kÃ¼Ã§Ã¼k, Ã§oÄŸunluÄŸu gÃ¶zlemsel Ã§alÄ±ÅŸmalara dayanmaktadÄ±r. Histolojik (biyopsi ile kanÄ±tlanmÄ±ÅŸ) bÃ¼yÃ¼k Ã¶lÃ§ekli RCT verileri henÃ¼z yoktur (<a href="https://pubmed.ncbi.nlm.nih.gov/39234763/" target="_blank" rel="noopener">Matteo et al., Expert Rev Gastroenterol Hepatol 2024; PMID: 39234763</a>).
</div>

<h2>ğŸˆ Ä°ntragastrik Balon (IGB) ve KaraciÄŸer YaÄŸlanmasÄ±</h2>

<p>Ä°ntragastrik balon, endoskopik olarak mideye yerleÅŸtirilen ve 6-12 ay sonra Ã§Ä±karÄ±lan, mide hacmini geÃ§ici olarak azaltan bir cihazdÄ±r. ESG'den farklÄ± olarak <strong>geÃ§ici bir mÃ¼dahaledir</strong> â€” balon Ã§Ä±karÄ±ldÄ±ktan sonra etki sÃ¼rdÃ¼rÃ¼lebilirliÄŸi hastanÄ±n yaÅŸam tarzÄ± deÄŸiÅŸikliÄŸine baÄŸlÄ±dÄ±r.</p>

<div class="study-card">
<h4>ğŸŸ¡ Aoko et al. â€” IGB ve NAFLD Parametreleri Meta-Analizi (2024)</h4>
<div class="study-detail"><strong>Kaynak:</strong> Aliment Pharmacol Ther 2024;59(1):8-22 (<a href="https://pubmed.ncbi.nlm.nih.gov/37986213/" target="_blank" rel="noopener">PMID: 37986213</a>)</div>
<div class="study-detail"><strong>PopÃ¼lasyon:</strong> 19 Ã§alÄ±ÅŸma, toplam 911 obez NAFLD hastasÄ±</div>
<div class="study-detail"><strong>MÃ¼dahale:</strong> Ã‡eÅŸitli intragastrik balon tipleri</div>
<div class="study-detail"><strong>SonuÃ§lar:</strong>
<ul>
<li>NAFLD aktivite skoru (NAS): âˆ’3.0 (95% GA: âˆ’2.41, âˆ’3.59)</li>
<li>ALT: âˆ’10.40 U/L (95% GA: âˆ’7.31, âˆ’13.49)</li>
<li>KaraciÄŸer steatozu (CAP): âˆ’37.76 dB/m (95% GA: âˆ’21.59, âˆ’53.92)</li>
<li>Ek olarak vÃ¼cut aÄŸÄ±rlÄ±ÄŸÄ±, BMI, HbA1c ve HOMA-IR'de anlamlÄ± dÃ¼ÅŸÃ¼ÅŸ</li>
</ul></div>
<div class="study-detail"><strong>âš ï¸ SÄ±nÄ±rlÄ±lÄ±k:</strong> Ã‡alÄ±ÅŸmalarÄ±n Ã§oÄŸu tek kollu (kontrol grupsuz) ve retrospektif. Balon Ã§Ä±karÄ±ldÄ±ktan sonra uzun dÃ¶nem karaciÄŸer parametrelerinin takibi sÄ±nÄ±rlÄ±. RCT verisi Ã§ok az.</div>
</div>

<div class="study-card">
<h4>ğŸ”´ Salomone et al. â€” IGB ve Ä°leri Fibrozis (2021)</h4>
<div class="study-detail"><strong>Kaynak:</strong> Liver Int 2021;41(9):2112-2116 (<a href="https://pubmed.ncbi.nlm.nih.gov/33938630/" target="_blank" rel="noopener">PMID: 33938630</a>)</div>
<div class="study-detail"><strong>PopÃ¼lasyon:</strong> 26 obez hasta, karaciÄŸer sertliÄŸi â‰¥9.7 KPa (F3-F4)</div>
<div class="study-detail"><strong>MÃ¼dahale:</strong> Orberaâ„¢ sÄ±vÄ± dolgulu IGB, 6 ay</div>
<div class="study-detail"><strong>SonuÃ§lar:</strong> AnlamlÄ± kilo kaybÄ± (106â†’92 kg); karaciÄŸer sertliÄŸinde dÃ¼ÅŸÃ¼ÅŸ (13.3â†’11.3 KPa, P &lt; 0.001); CAP'ta dÃ¼ÅŸÃ¼ÅŸ (355â†’296 dB/m, P &lt; 0.01); FIB-4'te dÃ¼ÅŸÃ¼ÅŸ</div>
<div class="study-detail"><strong>âš ï¸ SÄ±nÄ±rlÄ±lÄ±k:</strong> Retrospektif, tek merkezli, Ã§ok kÃ¼Ã§Ã¼k Ã¶rneklem (N=26), kontrol grubu yok. ğŸ”´ Erken kanÄ±t.</div>
</div>

<h2>ğŸ’Š Farmakolojik Tedaviler: GLP-1 ve Resmetirom</h2>

<h3>Semaglutid ve MASH: Faz 2'den Faz 3'e</h3>

<p>GLP-1 reseptÃ¶r agonistleri, MASLD/MASH tedavisinde en gÃ¼Ã§lÃ¼ farmakolojik kanÄ±t tabanÄ±na sahip ilaÃ§ sÄ±nÄ±fÄ±dÄ±r. Ä°ki Ã¶nemli Ã§alÄ±ÅŸmayÄ± inceleyelim:</p>

<div class="study-card">
<h4>ğŸŸ¢ Newsome et al. â€” Semaglutid Faz 2 NASH Ã‡alÄ±ÅŸmasÄ± (2021)</h4>
<div class="study-detail"><strong>Kaynak:</strong> N Engl J Med 2021;384(12):1113-1124 (<a href="https://pubmed.ncbi.nlm.nih.gov/33185364/" target="_blank" rel="noopener">PMID: 33185364</a>)</div>
<div class="study-detail"><strong>PopÃ¼lasyon:</strong> 320 biyopsi ile kanÄ±tlanmÄ±ÅŸ NASH hastasÄ± (F1-F3)</div>
<div class="study-detail"><strong>MÃ¼dahale:</strong> GÃ¼nlÃ¼k subkutan semaglutid 0.1/0.2/0.4 mg vs plasebo, 72 hafta</div>
<div class="study-detail"><strong>Primer sonuÃ§ (NASH rezolÃ¼syonu):</strong> 0.4 mg grubunda <strong>%59</strong> vs plasebo <strong>%17</strong> (P &lt; 0.001)</div>
<div class="study-detail"><strong>Fibrozis iyileÅŸmesi:</strong> 0.4 mg grubunda %43 vs plasebo %33 â€” <strong>istatistiksel olarak anlamlÄ± deÄŸil (P = 0.48)</strong></div>
<div class="study-detail"><strong>Kilo kaybÄ±:</strong> 0.4 mg grubunda ortalama %13</div>
<div class="study-detail"><strong>âš ï¸ Ã–nemli:</strong> NASH rezolÃ¼syonunda gÃ¼Ã§lÃ¼ etki, ancak fibrozis iyileÅŸmesinde anlamlÄ±lÄ±k saÄŸlanamamasÄ± Faz 3'Ã¼ zorunlu kÄ±ldÄ±.</div>
</div>

<div class="study-card">
<h4>ğŸŸ¢ ESSENCE Faz 3 â€” Semaglutid 2.4 mg ve MASH (2025)</h4>
<div class="study-detail"><strong>Kaynak:</strong> N Engl J Med 2025;392(21):2089-2099 (<a href="https://pubmed.ncbi.nlm.nih.gov/40305708/" target="_blank" rel="noopener">PMID: 40305708</a>)</div>
<div class="study-detail"><strong>PopÃ¼lasyon:</strong> 800 hasta (KÄ±sÄ±m 1), biyopsi ile kanÄ±tlanmÄ±ÅŸ MASH, F2-F3 fibrozis</div>
<div class="study-detail"><strong>MÃ¼dahale:</strong> HaftalÄ±k subkutan semaglutid 2.4 mg vs plasebo, 72 hafta</div>
<div class="study-detail"><strong>Primer sonuÃ§lar:</strong>
<ul>
<li>MASH rezolÃ¼syonu (fibrozis kÃ¶tÃ¼leÅŸmeden): semaglutid <strong>%62.9</strong> vs plasebo %34.3 (P &lt; 0.001)</li>
<li>Fibrozis iyileÅŸmesi (â‰¥1 evre, MASH kÃ¶tÃ¼leÅŸmeden): semaglutid <strong>%36.8</strong> vs plasebo %22.4 (P &lt; 0.001)</li>
<li>Her iki primer sonlanÄ±m birlikte: semaglutid %32.7 vs plasebo %16.1 (P &lt; 0.001)</li>
</ul></div>
<div class="study-detail"><strong>Kilo kaybÄ±:</strong> Semaglutid grubunda âˆ’%10.5 vs plasebo âˆ’%2.0</div>
<div class="study-detail"><strong>âš ï¸ SÄ±nÄ±rlÄ±lÄ±k:</strong> 72 haftalÄ±k ara analiz â€” 240 haftalÄ±k tam Ã§alÄ±ÅŸma devam ediyor. Uzun dÃ¶nem karaciÄŸer Ã§Ä±ktÄ±larÄ± (siroz, transplantasyon ihtiyacÄ±, mortalite) henÃ¼z bilinmiyor.</div>
</div>

<div class="evidence-positive">
<strong>ğŸŸ¢ ESSENCE Ã§alÄ±ÅŸmasÄ±, semaglutid 2.4 mg'Ä±n hem MASH rezolÃ¼syonu hem de fibrozis iyileÅŸmesinde plaseboya Ã¼stÃ¼nlÃ¼ÄŸÃ¼nÃ¼ Faz 3 dÃ¼zeyinde kanÄ±tlayan ilk GLP-1 Ã§alÄ±ÅŸmasÄ±dÄ±r.</strong> Faz 2'de fibrozis iyileÅŸmesindeki yetersizlik, Faz 3'te daha yÃ¼ksek doz (2.4 mg/hafta) ile aÅŸÄ±lmÄ±ÅŸtÄ±r.
</div>

<h3>Resmetirom (Rezdiffra): Ä°lk FDA OnaylÄ± MASH Ä°lacÄ±</h3>

<div class="study-card">
<h4>ğŸŸ¢ MAESTRO-NASH â€” Resmetirom Faz 3 (2024)</h4>
<div class="study-detail"><strong>Kaynak:</strong> N Engl J Med 2024;390(6):497-509 (<a href="https://pubmed.ncbi.nlm.nih.gov/38324483/" target="_blank" rel="noopener">PMID: 38324483</a>)</div>
<div class="study-detail"><strong>PopÃ¼lasyon:</strong> 966 hasta, biyopsi ile kanÄ±tlanmÄ±ÅŸ NASH, F1B-F3 fibrozis</div>
<div class="study-detail"><strong>MÃ¼dahale:</strong> Resmetirom 80 mg veya 100 mg/gÃ¼n vs plasebo, 52 hafta</div>
<div class="study-detail"><strong>Primer sonuÃ§lar:</strong>
<ul>
<li>NASH rezolÃ¼syonu: 80 mg %25.9, 100 mg %29.9 vs plasebo ~%10 (P &lt; 0.001)</li>
<li>Fibrozis iyileÅŸmesi: her iki doz plaseboya Ã¼stÃ¼n (P &lt; 0.001)</li>
</ul></div>
<div class="study-detail"><strong>Ek bulgular:</strong> LDL âˆ’%13.6 (80 mg), âˆ’%16.3 (100 mg); aterojenik lipidlerde anlamlÄ± dÃ¼ÅŸÃ¼ÅŸ</div>
<div class="study-detail"><strong>âš ï¸ SÄ±nÄ±rlÄ±lÄ±k:</strong> <strong>HÄ±zlandÄ±rÄ±lmÄ±ÅŸ onay</strong> (accelerated approval) â€” klinik sonlanÄ±m verisi (siroz, mortalite) doÄŸrulayÄ±cÄ± Ã§alÄ±ÅŸmadan gelecek. Uzun dÃ¶nem gÃ¼venlik profili henÃ¼z netleÅŸmemiÅŸ. TÃ¼rkiye'de henÃ¼z ruhsatlÄ± deÄŸil.</div>
</div>

<p>Resmetirom, Mart 2024'te FDA tarafÄ±ndan <strong>sirotik olmayan NASH/MASH (F2-F3 fibrozis)</strong> tedavisi iÃ§in onaylanan ilk ilaÃ§tÄ±r (<a href="https://pubmed.ncbi.nlm.nih.gov/38771485/" target="_blank" rel="noopener">Keam, Drugs 2024; PMID: 38771485</a>). Tiroid hormon reseptÃ¶r-Î² (THR-Î²) selektif agonisti olarak, kilo kaybÄ±ndan baÄŸÄ±msÄ±z olarak karaciÄŸer yaÄŸÄ±nÄ± ve inflamasyonu hedefler. Bu, GLP-1 agonistlerinden farklÄ± bir etki mekanizmasÄ±dÄ±r.</p>

<h2>âš–ï¸ KarÅŸÄ±laÅŸtÄ±rma: Cerrahi vs Endoskopik vs Farmakolojik</h2>

<p>DÃ¼rÃ¼st bir karÅŸÄ±laÅŸtÄ±rma yapmak kritik Ã¶nem taÅŸÄ±r. <strong>Bariatrik cerrahi, kilo kaybÄ± ve MASLD iyileÅŸmesinde en etkili yÃ¶ntemdir</strong> â€” bu gerÃ§eÄŸi gizlemek bilimsel dÃ¼rÃ¼stlÃ¼ÄŸe aykÄ±rÄ± olur.</p>

<table class="comparison-table">
<thead>
<tr>
<th>Parametre</th>
<th>YaÅŸam TarzÄ±</th>
<th>GLP-1 (Semaglutid 2.4mg)</th>
<th>Endoskopik (ESG/IGB)</th>
<th>Cerrahi (RYGB/SG)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ortalama kilo kaybÄ±</strong></td>
<td>%3-5</td>
<td>%10-15</td>
<td>%10-18 (ESG); %10-15 (IGB)</td>
<td>%25-35</td>
</tr>
<tr>
<td><strong>MASH rezolÃ¼syonu</strong></td>
<td>SÄ±nÄ±rlÄ± veri</td>
<td>%59-63 (Faz 2-3)</td>
<td>Biyopsi verisi yetersiz</td>
<td>%80-90 (gÃ¶zlemsel)</td>
</tr>
<tr>
<td><strong>Fibrozis iyileÅŸmesi</strong></td>
<td>â‰¥%10 kilo kaybÄ± ile mÃ¼mkÃ¼n</td>
<td>%37 (ESSENCE)</td>
<td>Non-invaziv testlerde iyileÅŸme</td>
<td>GÃ¶zlemsel Ã§alÄ±ÅŸmalarda gÃ¼Ã§lÃ¼</td>
</tr>
<tr>
<td><strong>Ä°nvazivlik</strong></td>
<td>Yok</td>
<td>Yok (enjeksiyon)</td>
<td>DÃ¼ÅŸÃ¼k (endoskopik)</td>
<td>YÃ¼ksek (cerrahi)</td>
</tr>
<tr>
<td><strong>Geri dÃ¶nÃ¼ÅŸebilirlik</strong></td>
<td>â€”</td>
<td>Ä°laÃ§ bÄ±rakÄ±lÄ±rsa kilo geri alÄ±mÄ±</td>
<td>IGB: geÃ§ici; ESG: kÄ±smen geri dÃ¶nÃ¼ÅŸÃ¼mlÃ¼</td>
<td>KalÄ±cÄ± anatomik deÄŸiÅŸiklik</td>
</tr>
<tr>
<td><strong>KanÄ±t dÃ¼zeyi (MASLD)</strong></td>
<td>ğŸŸ¢ GÃ¼Ã§lÃ¼</td>
<td>ğŸŸ¢ GÃ¼Ã§lÃ¼ (RCT)</td>
<td>ğŸŸ¡ Orta (kÃ¼Ã§Ã¼k Ã§alÄ±ÅŸmalar)</td>
<td>ğŸŸ¡ Orta (gÃ¶zlemsel, RCT yok)</td>
</tr>
<tr>
<td><strong>Komplikasyon riski</strong></td>
<td>Minimal</td>
<td>GI yan etkiler %40-60</td>
<td>DÃ¼ÅŸÃ¼k (%1-2 ciddi)</td>
<td>Orta (%3-5 ciddi)</td>
</tr>
</tbody>
</table>

<div class="evidence-negative">
<strong>ğŸ”´ Negatif KanÄ±t ve SÄ±nÄ±rlÄ±lÄ±klar â€” Endoskopik ProsedÃ¼rler:</strong>
<ul>
<li><strong>Spesifik endikasyon yokluÄŸu:</strong> ESG ve IGB, MASLD/MASH iÃ§in spesifik olarak onaylanmamÄ±ÅŸtÄ±r. KullanÄ±m, obezite tedavisi Ã§erÃ§evesinde dolaylÄ± olarak gerÃ§ekleÅŸir.</li>
<li><strong>Histolojik veri eksikliÄŸi:</strong> ESG ile yapÄ±lan Ã§alÄ±ÅŸmalarÄ±n bÃ¼yÃ¼k Ã§oÄŸunluÄŸu non-invaziv testlere (FibroScan, HSI, NFS) dayanÄ±r â€” karaciÄŸer biyopsisi ile doÄŸrulanmÄ±ÅŸ veri Ã§ok azdÄ±r (PMID: 39234763).</li>
<li><strong>Uzun dÃ¶nem takip yetersizliÄŸi:</strong> ESG'nin karaciÄŸer Ã¼zerine etkisine dair 2-3 yÄ±ldan uzun takip verisi bulunmamaktadÄ±r.</li>
<li><strong>KÃ¼Ã§Ã¼k Ã¶rneklemler:</strong> Mevcut en gÃ¼Ã§lÃ¼ kanÄ±t olan RCT (PMID: 39694202) bile yalnÄ±zca 40 hasta iÃ§erir.</li>
<li><strong>Cerrahi Ã¼stÃ¼nlÃ¼ÄŸÃ¼:</strong> Bariatrik cerrahi, kilo kaybÄ± ve MASH iyileÅŸmesinde endoskopik prosedÃ¼rlerden tutarlÄ± biÃ§imde daha etkilidir. Cerrahi ihtiyacÄ± olan uygun hastalarda endoskopik yÃ¶ntemlerin cerrahi yerine Ã¶nerilmesi uygun deÄŸildir.</li>
<li><strong>IGB geÃ§iciliÄŸi:</strong> Balon 6-12 ay sonra Ã§Ä±karÄ±lÄ±r; uzun dÃ¶nem kilo ve karaciÄŸer parametreleri sÃ¼rdÃ¼rÃ¼lebilirliÄŸi belirsizdir.</li>
</ul>
</div>

<h2>ğŸ”— Kombinasyon YaklaÅŸÄ±mÄ±: ESG + GLP-1?</h2>

<p>Endoskopik prosedÃ¼rler ile farmakolojik tedavinin kombinasyonu, henÃ¼z kanÄ±t dÃ¼zeyi dÃ¼ÅŸÃ¼k olmakla birlikte, mantÄ±ksal olarak Ã§ekici bir stratejidir:</p>

<div class="highlight-box">
<strong>Teorik avantajlar:</strong>
<ul>
<li><strong>ESG</strong> mekanik kÄ±sÄ±tlama ile porsiyon kontrolÃ¼ ve erken doyma saÄŸlar</li>
<li><strong>GLP-1 agonistleri</strong> merkezi iÅŸtah baskÄ±lama, mide boÅŸalma yavaÅŸlatma ve doÄŸrudan hepatoprotektif etki sunar</li>
<li>Kombinasyon, tek baÅŸÄ±na her iki yÃ¶ntemden daha yÃ¼ksek ve sÃ¼rdÃ¼rÃ¼lebilir kilo kaybÄ± saÄŸlayabilir</li>
<li>GLP-1'in MASLD Ã¼zerindeki direkt etkileri (kilo kaybÄ±ndan baÄŸÄ±msÄ±z inflamasyon azaltma) ESG'nin dolaylÄ± etkisini tamamlayabilir</li>
</ul>
<p style="margin-bottom:0;"><strong>âš ï¸ KanÄ±t durumu:</strong> ğŸ”´ Erken kanÄ±t. ESG + GLP-1 kombinasyonunun MASLD Ã¼zerine etkisini spesifik olarak deÄŸerlendiren RCT bulunmamaktadÄ±r. Bu yaklaÅŸÄ±m henÃ¼z klinik araÅŸtÄ±rma aÅŸamasÄ±ndadÄ±r.</p>
</div>

<h2>ğŸ‡¹ğŸ‡· TÃ¼rkiye'de Durum</h2>

<div class="turkey-box">
<h4>ğŸ‡¹ğŸ‡· TÃ¼rkiye'deki EriÅŸim ve Uygulama</h4>
<ul>
<li><strong>ESG:</strong> TÃ¼rkiye'de deneyimli merkezlerde uygulanmaktadÄ±r. SGK kapsamÄ±nda deÄŸildir; Ã¶zel saÄŸlÄ±k sigortasÄ± kapsamÄ± deÄŸiÅŸkendir.</li>
<li><strong>Ä°ntragastrik balon:</strong> YaygÄ±n olarak eriÅŸilebilir; hem devlet hem Ã¶zel hastanelerde uygulanmaktadÄ±r.</li>
<li><strong>Semaglutid (Ozempic/Wegovy):</strong> Ozempic (diyabet endikasyonu) TÃ¼rkiye'de ruhsatlÄ±dÄ±r; Wegovy (obezite endikasyonu) henÃ¼z ruhsat almamÄ±ÅŸtÄ±r. EriÅŸim sÄ±nÄ±rlÄ±dÄ±r.</li>
<li><strong>Resmetirom (Rezdiffra):</strong> TÃ¼rkiye'de henÃ¼z ruhsatlÄ± deÄŸildir.</li>
<li><strong>MASLD taramasÄ±:</strong> Obezite, Tip 2 diyabet veya metabolik sendrom tanÄ±lÄ± hastalarda karaciÄŸer yaÄŸlanmasÄ± taramasÄ± (ultrason + FibroScan) Ã¶nerilmektedir ancak sistematik tarama programÄ± yoktur.</li>
</ul>
</div>

<h2>ğŸ“Š Tedavi AlgoritmasÄ±: Kime Ne Zaman?</h2>

<div class="evidence-box">
<h3 style="margin-top:0;">MASLD'de BasamaklÄ± YaklaÅŸÄ±m (GÃ¼ncel KanÄ±tlar IÅŸÄ±ÄŸÄ±nda)</h3>
<ol>
<li><strong>TÃ¼m hastalar:</strong> YaÅŸam tarzÄ± mÃ¼dahalesi (diyet + egzersiz) â€” hedef â‰¥%7-10 kilo kaybÄ± (EASL 2024)</li>
<li><strong>YaÅŸam tarzÄ± ile yeterli kilo kaybÄ± saÄŸlanamayanlar:</strong>
<ul>
<li>BMI â‰¥27 + MASLD: GLP-1 RA (semaglutid) â€” en gÃ¼Ã§lÃ¼ kanÄ±t tabanÄ± ğŸŸ¢</li>
<li>MASH + F2-F3 fibrozis: Resmetirom (FDA onaylÄ±, TÃ¼rkiye'de henÃ¼z eriÅŸilemez)</li>
</ul>
</li>
<li><strong>BMI â‰¥30 + yetersiz farmakolojik yanÄ±t veya farmakolojik tedaviye uyum sorunu:</strong>
<ul>
<li>Endoskopik prosedÃ¼rler (ESG veya IGB) â€” dolaylÄ± fayda, cerrahiye kÃ¶prÃ¼ veya cerrahi istemeyen/uygun olmayan hastalar iÃ§in alternatif ğŸŸ¡</li>
</ul>
</li>
<li><strong>BMI â‰¥35 veya BMI â‰¥30 + ciddi komorbidite:</strong>
<ul>
<li>Bariatrik cerrahi â€” en yÃ¼ksek kilo kaybÄ± ve MASLD iyileÅŸme oranlarÄ±</li>
</ul>
</li>
</ol>
<p style="margin-bottom:0; font-size:0.9rem; color:#6B7280;"><em>Bu algoritma mevcut kanÄ±tlarÄ±n bir sentezi olup, bireysel tedavi planlamasÄ± mutlaka uzman hekim tarafÄ±ndan yapÄ±lmalÄ±dÄ±r.</em></p>
</div>

<h2>ğŸ”® Gelecek Perspektifi</h2>

<p>MASLD tedavisinde Ã¶nÃ¼mÃ¼zdeki 3-5 yÄ±lda beklenen geliÅŸmeler:</p>

<ul>
<li><strong>ESSENCE tam sonuÃ§larÄ± (240 hafta):</strong> Semaglutid'in uzun dÃ¶nem karaciÄŸer Ã§Ä±ktÄ±larÄ± (siroz progresyonu, karaciÄŸer ile iliÅŸkili Ã¶lÃ¼m) netleÅŸecek</li>
<li><strong>ESG + farmakolojik tedavi kombinasyon RCT'leri:</strong> BirÃ§ok merkez ESG + GLP-1 kombinasyonunu araÅŸtÄ±rmaya baÅŸlamÄ±ÅŸtÄ±r</li>
<li><strong>Tirzepatid (dual agonist) ve MASH:</strong> GIP/GLP-1 dual agonistinin MASH Ã¼zerine etkisi araÅŸtÄ±rÄ±lmaktadÄ±r</li>
<li><strong>Yeni farmakolojik hedefler:</strong> FGF21 analoglarÄ±, pan-PPAR agonistleri ve kombinasyon rejimleri</li>
<li><strong>Non-invaziv biyobelirteÃ§ler:</strong> KaraciÄŸer biyopsisine alternatif, gÃ¼venilir non-invaziv MASH tanÄ± yÃ¶ntemlerinin geliÅŸtirilmesi (bu, endoskopik prosedÃ¼rlerin etkinliÄŸini daha bÃ¼yÃ¼k Ã§alÄ±ÅŸmalarda deÄŸerlendirmeyi kolaylaÅŸtÄ±racak)</li>
</ul>

<h2>ğŸ“Œ SonuÃ§</h2>

<p>KaraciÄŸer yaÄŸlanmasÄ± (MASLD), dÃ¼nya genelinde en yaygÄ±n kronik karaciÄŸer hastalÄ±ÄŸÄ±dÄ±r ve TÃ¼rkiye'de her iki yetiÅŸkinden birini etkilemektedir. Tedavinin temeli kilo kaybÄ±dÄ±r â€” ancak yeterli kilo kaybÄ±na ulaÅŸmak Ã§oÄŸu hasta iÃ§in zordur.</p>

<p>Endoskopik bariatrik prosedÃ¼rler (ESG ve intragastrik balon), cerrahi ile yaÅŸam tarzÄ± mÃ¼dahalesi arasÄ±nda anlamlÄ± bir ara basamak sunmaktadÄ±r. Mevcut kanÄ±tlar, bu prosedÃ¼rlerin karaciÄŸer parametrelerinde iyileÅŸme saÄŸladÄ±ÄŸÄ±nÄ± gÃ¶stermektedir â€” ancak <strong>veriler henÃ¼z kÃ¼Ã§Ã¼k Ã§alÄ±ÅŸmalara dayanmaktadÄ±r ve MASLD iÃ§in spesifik endikasyon yoktur</strong>.</p>

<p>GLP-1 agonistleri (Ã¶zellikle semaglutid) MASH tedavisinde en gÃ¼Ã§lÃ¼ farmakolojik kanÄ±t tabanÄ±na sahipken, resmetirom ilk FDA onaylÄ± MASH ilacÄ± olarak yeni bir dÃ¶nem baÅŸlatmÄ±ÅŸtÄ±r. GeleceÄŸin tedavi yaklaÅŸÄ±mÄ±, muhtemelen yaÅŸam tarzÄ± + farmakolojik + endoskopik/cerrahi mÃ¼dahalelerin <strong>kiÅŸiselleÅŸtirilmiÅŸ kombinasyonlarÄ±</strong> olacaktÄ±r.</p>

<div class="warning-box">
<h4>âš ï¸ Hastalar Ä°Ã§in Not</h4>
<p>KaraciÄŸer yaÄŸlanmasÄ± tanÄ±sÄ± almÄ±ÅŸ veya risk altÄ±ndaysanÄ±z, tedavi seÃ§eneklerinizi mutlaka <strong>gastroenteroloji ve/veya hepatoloji uzmanÄ±</strong> ile birlikte deÄŸerlendirin. Bu yazÄ±da sunulan bilgiler genel bilgilendirme amaÃ§lÄ±dÄ±r ve bireysel tÄ±bbi tavsiye yerine geÃ§mez.</p>
</div>

<h2>ğŸ“š Kaynaklar</h2>

<ol style="font-size:0.95rem;">
<li>Rinella ME, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. <em>Hepatology</em> 2023;78(6):1966-86. <a href="https://pubmed.ncbi.nlm.nih.gov/37363821/" target="_blank" rel="noopener">PMID: 37363821</a></li>
<li>Nunes BCM, et al. Impact of Endoscopic Sleeve Gastroplasty in Non-alcoholic Fatty Liver Disease: a Systematic Review and Meta-analysis. <em>Obes Surg</em> 2023;33(9):2917-2926. <a href="https://pubmed.ncbi.nlm.nih.gov/37537506/" target="_blank" rel="noopener">PMID: 37537506</a></li>
<li>Llop E, et al. Endoscopic Sleeve Gastroplasty Plus Lifestyle Intervention in Patients With MASH: A Multicenter, Sham-controlled, Randomized Trial. <em>Clin Gastroenterol Hepatol</em> 2025;23(9):1556-1566. <a href="https://pubmed.ncbi.nlm.nih.gov/39694202/" target="_blank" rel="noopener">PMID: 39694202</a></li>
<li>Aoko O, et al. Meta-analysis: Impact of intragastric balloon therapy on NAFLD-related parameters in patients with obesity. <em>Aliment Pharmacol Ther</em> 2024;59(1):8-22. <a href="https://pubmed.ncbi.nlm.nih.gov/37986213/" target="_blank" rel="noopener">PMID: 37986213</a></li>
<li>Salomone F, et al. Effects of intragastric balloon in patients with nonalcoholic fatty liver disease and advanced fibrosis. <em>Liver Int</em> 2021;41(9):2112-2116. <a href="https://pubmed.ncbi.nlm.nih.gov/33938630/" target="_blank" rel="noopener">PMID: 33938630</a></li>
<li>Newsome PN, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. <em>N Engl J Med</em> 2021;384(12):1113-1124. <a href="https://pubmed.ncbi.nlm.nih.gov/33185364/" target="_blank" rel="noopener">PMID: 33185364</a></li>
<li>Sanyal AJ, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE). <em>N Engl J Med</em> 2025;392(21):2089-2099. <a href="https://pubmed.ncbi.nlm.nih.gov/40305708/" target="_blank" rel="noopener">PMID: 40305708</a></li>
<li>Harrison SA, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis (MAESTRO-NASH). <em>N Engl J Med</em> 2024;390(6):497-509. <a href="https://pubmed.ncbi.nlm.nih.gov/38324483/" target="_blank" rel="noopener">PMID: 38324483</a></li>
<li>Keam SJ. Resmetirom: First Approval. <em>Drugs</em> 2024;84(6):729-735. <a href="https://pubmed.ncbi.nlm.nih.gov/38771485/" target="_blank" rel="noopener">PMID: 38771485</a></li>
<li>Matteo MV, et al. Endoscopic sleeve gastroplasty for metabolic dysfunction-associated steatotic liver disease. <em>Expert Rev Gastroenterol Hepatol</em> 2024;18(8):397-405. <a href="https://pubmed.ncbi.nlm.nih.gov/39234763/" target="_blank" rel="noopener">PMID: 39234763</a></li>
<li>EASL-EASD-EASO Clinical Practice Guidelines on the management of MASLD. <em>J Hepatol</em> 2024. <a href="https://pubmed.ncbi.nlm.nih.gov/38851997/" target="_blank" rel="noopener">PMID: 38851997</a></li>
<li>YÄ±lmaz Y, et al. The Changing Prevalence of NAFLD in Turkey in the Last Decade. <em>Turk J Gastroenterol</em> 2021. <a href="https://pubmed.ncbi.nlm.nih.gov/34160360/" target="_blank" rel="noopener">PMID: 34160360</a></li>
</ol>

<!-- Ä°LGÄ°LÄ° YAZILAR -->
<div style="margin-top:3rem;">
  <h3 style="font-size:1.2rem; font-weight:700; margin-bottom:1.25rem; color:var(--text);">ğŸ“– Ä°lgili YazÄ±lar</h3>
  <div style="display:flex; flex-wrap:wrap; gap:1rem;">

      <a href="esg-endoskopik-sleeve-rehber.html" class="related-post-card" style="text-decoration:none; color:inherit; display:block; background:#fff; border:1px solid #e5e7eb; border-radius:12px; padding:1.25rem; transition:all 0.2s ease; flex:1; min-width:250px;">
        <div style="display:flex; align-items:center; gap:8px; margin-bottom:0.75rem;">
          <span style="font-size:1.2rem;">ğŸ’Š</span>
          <span style="font-size:0.75rem; font-weight:600; color:#EC4899; text-transform:uppercase; letter-spacing:0.5px;">Tedavi</span>
        </div>
        <h4 style="font-size:0.95rem; font-weight:600; color:#195157; margin-bottom:0.5rem; line-height:1.4;">Endoskopik Sleeve Gastroplasti (ESG) KapsamlÄ± Rehberi</h4>
        <p style="font-size:0.85rem; color:#6B7280; line-height:1.5; margin:0;">AmeliyatsÄ±z mide kÃ¼Ã§Ã¼ltme: ESG nasÄ±l yapÄ±lÄ±r, ne kadar kilo verdirir, riskleri neler?</p>
      </a>

      <a href="mide-balonu-tedavisi-kime-uygun-sonuclar-nasil.html" class="related-post-card" style="text-decoration:none; color:inherit; display:block; background:#fff; border:1px solid #e5e7eb; border-radius:12px; padding:1.25rem; transition:all 0.2s ease; flex:1; min-width:250px;">
        <div style="display:flex; align-items:center; gap:8px; margin-bottom:0.75rem;">
          <span style="font-size:1.2rem;">ğŸ’Š</span>
          <span style="font-size:0.75rem; font-weight:600; color:#EC4899; text-transform:uppercase; letter-spacing:0.5px;">Tedavi</span>
        </div>
        <h4 style="font-size:0.95rem; font-weight:600; color:#195157; margin-bottom:0.5rem; line-height:1.4;">Mide Balonu Tedavisi: Kime Uygun, SonuÃ§lar NasÄ±l?</h4>
        <p style="font-size:0.85rem; color:#6B7280; line-height:1.5; margin:0;">Mide balonu tedavisi hakkÄ±nda bilmeniz gerekenler: baÅŸarÄ± oranlarÄ±, riskler ve uygulamalar.</p>
      </a>

      <a href="glp1-tam-rehber.html" class="related-post-card" style="text-decoration:none; color:inherit; display:block; background:#fff; border:1px solid #e5e7eb; border-radius:12px; padding:1.25rem; transition:all 0.2s ease; flex:1; min-width:250px;">
        <div style="display:flex; align-items:center; gap:8px; margin-bottom:0.75rem;">
          <span style="font-size:1.2rem;">ğŸ’Š</span>
          <span style="font-size:0.75rem; font-weight:600; color:#EC4899; text-transform:uppercase; letter-spacing:0.5px;">Tedavi</span>
        </div>
        <h4 style="font-size:0.95rem; font-weight:600; color:#195157; margin-bottom:0.5rem; line-height:1.4;">GLP-1 Ä°laÃ§larÄ± Tam Rehberi: Ozempic, Wegovy, Mounjaro</h4>
        <p style="font-size:0.85rem; color:#6B7280; line-height:1.5; margin:0;">Semaglutid ve tirzepatid nasÄ±l Ã§alÄ±ÅŸÄ±r? Ne kadar kilo verdirir? TÃ¼m klinik veriler.</p>
      </a>
  </div>
  <style>
    .related-post-card:hover { transform:translateY(-2px); box-shadow:0 4px 12px rgba(0,0,0,0.1); border-color:#14919B !important; }
    @media(max-width:768px) { .related-post-card { min-width:100% !important; } }
  </style>
</div>
<!-- END Ä°LGÄ°LÄ° YAZILAR -->

<div class="cta-box">
  <h3>ğŸ©º Endobariatrik Tedavi SeÃ§enekleri HakkÄ±nda</h3>
  <p>ESG, intragastrik balon ve diÄŸer endoskopik tedavi seÃ§enekleri hakkÄ±nda detaylÄ± bilgi almak iÃ§in kapsamlÄ± rehberlerimizi inceleyin.</p>
  <a href="esg-vs-sleeve-gastrektomi.html" class="cta-btn">ESG vs Cerrahi KarÅŸÄ±laÅŸtÄ±rmasÄ± â†’</a>
</div>

 </div>
 </article>

<script src="/scripts/premium-animations.js" defer></script>
</body>
</html>
